$CCEL
CRYO CELL INTERNATIONAL INC

2023 Q3 Form 10-Q Financial Statement

#000095017023033057 Filed on July 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $7.870M $7.773M
YoY Change 2.46% 1.83%
Cost Of Revenue $2.156M $2.143M
YoY Change -8.2% -2.65%
Gross Profit $5.714M $5.630M
YoY Change 7.15% 3.64%
Gross Profit Margin 72.6% 72.43%
Selling, General & Admin $3.805M $4.039M
YoY Change 5.58% 3.23%
% of Gross Profit 66.59% 71.75%
Research & Development $344.1K $304.7K
YoY Change 328.71% 276.63%
% of Gross Profit 6.02% 5.41%
Depreciation & Amortization $338.9K $354.9K
YoY Change -8.17% -2.66%
% of Gross Profit 5.93% 6.31%
Operating Expenses $4.149M $4.602M
YoY Change 12.62% 15.23%
Operating Profit $1.161M $1.028M
YoY Change 21.66% -13.94%
Interest Expense $469.6K -$683.6K
YoY Change 28.55% -347.19%
% of Operating Profit 40.45% -66.5%
Other Income/Expense, Net -$93.42K $2.070K
YoY Change -70.19% -100.7%
Pretax Income $1.068M $346.4K
YoY Change 66.56% -61.5%
Income Tax $387.1K $125.4K
% Of Pretax Income 36.25% 36.21%
Net Earnings $680.6K $221.0K
YoY Change 45.79% -65.18%
Net Earnings / Revenue 8.65% 2.84%
Basic Earnings Per Share $0.08 $0.03
Diluted Earnings Per Share $0.08 $0.03
COMMON SHARES
Basic Shares Outstanding 8.288M 8.304M
Diluted Shares Outstanding 8.342M 8.332M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.207M $1.692M
YoY Change -59.25% -40.99%
Cash & Equivalents $584.0K $1.124M
Short-Term Investments $623.5K $568.2K
Other Short-Term Assets $450.6K $1.060M
YoY Change -64.43% 25.42%
Inventory $1.063M $879.3K
Prepaid Expenses $719.0K $650.5K
Receivables $6.438M $6.682M
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.936M $10.31M
YoY Change -10.81% 0.08%
LONG-TERM ASSETS
Property, Plant & Equipment $18.84M $18.29M
YoY Change 24.1% 353.98%
Goodwill $1.941M $1.941M
YoY Change 0.0% 0.0%
Intangibles $1.391M $1.415M
YoY Change -6.48% -6.38%
Long-Term Investments $308.0K $308.0K
YoY Change 0.0% 0.0%
Other Assets $41.02M $36.49M
YoY Change 1.43% -11.13%
Total Long-Term Assets $59.86M $58.44M
YoY Change 7.61% 29.62%
TOTAL ASSETS
Total Short-Term Assets $9.936M $10.31M
Total Long-Term Assets $59.86M $58.44M
Total Assets $69.80M $68.76M
YoY Change 4.54% 24.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.785M $4.056M
YoY Change 55.38% 135.48%
Accrued Expenses $1.774M $2.441M
YoY Change -18.79% 17.66%
Deferred Revenue $9.697M $9.456M
YoY Change 1.57% 1.77%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $162.7K $158.5K
YoY Change 5.45% -55.72%
Total Short-Term Liabilities $18.56M $19.71M
YoY Change -21.42% 25.44%
LONG-TERM LIABILITIES
Long-Term Debt $8.468M $8.506M
YoY Change -1.64%
Other Long-Term Liabilities $51.25M $41.40M
YoY Change 12.57% 17.36%
Total Long-Term Liabilities $51.25M $49.91M
YoY Change 12.57% 41.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.56M $19.71M
Total Long-Term Liabilities $51.25M $49.91M
Total Liabilities $69.81M $69.62M
YoY Change 0.96% 36.53%
SHAREHOLDERS EQUITY
Retained Earnings -$19.97M -$20.65M
YoY Change -11.15% 35.24%
Common Stock $43.38M $43.22M
YoY Change 1.85% 3.1%
Preferred Stock
YoY Change
Treasury Stock (at cost) $23.43M $23.42M
YoY Change 4.12% 5.33%
Treasury Stock Shares $6.561M
Shareholders Equity -$16.16K -$858.4K
YoY Change
Total Liabilities & Shareholders Equity $69.80M $68.76M
YoY Change 4.54% 24.12%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $680.6K $221.0K
YoY Change 45.79% -65.18%
Depreciation, Depletion And Amortization $338.9K $354.9K
YoY Change -8.17% -2.66%
Cash From Operating Activities $1.942M $1.989M
YoY Change -27.76% 2.15%
INVESTING ACTIVITIES
Capital Expenditures $3.291M $1.457M
YoY Change -129.28% -574.78%
Acquisitions
YoY Change
Other Investing Activities -$95.25K -$117.5K
YoY Change -844.14% -130.05%
Cash From Investing Activities -$3.386M -$1.575M
YoY Change -69.84% -1972.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 903.9K -663.2K
YoY Change -89.56% -51.64%
NET CHANGE
Cash From Operating Activities 1.942M 1.989M
Cash From Investing Activities -3.386M -1.575M
Cash From Financing Activities 903.9K -663.2K
Net Change In Cash -540.0K -249.1K
YoY Change -549.07% -137.75%
FREE CASH FLOW
Cash From Operating Activities $1.942M $1.989M
Capital Expenditures $3.291M $1.457M
Free Cash Flow -$1.349M $531.7K
YoY Change -109.68% -76.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000862692
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40767
dei Entity Registrant Name
EntityRegistrantName
CRYO-CELL INTERNATIONAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3023093
dei Entity Address Address Line1
EntityAddressAddressLine1
700 Brooker Creek Blvd
dei Entity Address City Or Town
EntityAddressCityOrTown
Oldsmar
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34677
dei City Area Code
CityAreaCode
813
dei Local Phone Number
LocalPhoneNumber
749-2100
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
CCEL
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8288414
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1123998
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1703958
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
568181
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
17620
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3633617
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3528119
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6682479
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
650466
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
566557
CY2023Q2 us-gaap Inventory Net
InventoryNet
879294
CY2022Q4 us-gaap Inventory Net
InventoryNet
851230
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
409059
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
426879
CY2023Q2 us-gaap Assets Current
AssetsCurrent
10313477
CY2022Q4 us-gaap Assets Current
AssetsCurrent
9610185
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17098064
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13603115
CY2023Q2 ccel Duke License Agreement
DukeLicenseAgreement
13210641
CY2022Q4 ccel Duke License Agreement
DukeLicenseAgreement
13691028
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1415121
CY2022Q4 us-gaap Liabilities
Liabilities
66412356
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1463312
CY2023Q2 us-gaap Inventory Noncurrent
InventoryNoncurrent
8836287
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
9275344
CY2023Q2 us-gaap Goodwill
Goodwill
1941411
CY2022Q4 us-gaap Goodwill
Goodwill
1941411
CY2023Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13742399
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
13742399
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1188284
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
606034
CY2023Q2 ccel Deposits And Other Assets
DepositsAndOtherAssets
704024
CY2022Q4 ccel Deposits And Other Assets
DepositsAndOtherAssets
647226
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41346167
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41674754
CY2023Q2 us-gaap Assets
Assets
68757708
CY2022Q4 us-gaap Assets
Assets
64888054
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4056242
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1605301
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2216727
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3585810
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
158456
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150527
CY2023Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
1772728
CY2022Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2272728
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
223974
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
224729
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297691
CY2023Q2 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1600000
CY2022Q4 ccel Duke License Agreement Liability Current
DukeLicenseAgreementLiabilityCurrent
1983036
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9455539
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9586327
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19708395
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19481420
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
38652511
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36000059
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
907379
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1162704
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
8505682
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8579875
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
967116
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
313298
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
875000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
49907688
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46930936
CY2023Q2 us-gaap Liabilities
Liabilities
69616083
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14848001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8287169
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14848001
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8500511
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
148480
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
148480
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43066971
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42597380
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
23424101
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
22632649
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20649725
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21637513
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68757708
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64888054
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7772690
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7633217
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15597105
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14891748
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2143186
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2201540
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4210550
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4304742
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4038968
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3912586
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7917871
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7288540
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-23124
CY2022Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-36105
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-187825
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-152538
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
304682
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80896
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
383516
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
228116
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
281080
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
279926
us-gaap Depreciation And Amortization
DepreciationAndAmortization
561924
us-gaap Depreciation And Amortization
DepreciationAndAmortization
558092
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
6744792
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
6438843
us-gaap Costs And Expenses
CostsAndExpenses
12886036
us-gaap Costs And Expenses
CostsAndExpenses
12226952
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1027898
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1194374
us-gaap Operating Income Loss
OperatingIncomeLoss
2711069
us-gaap Operating Income Loss
OperatingIncomeLoss
2664796
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
10377
CY2022Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-18188
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6696
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-26830
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2066
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3334
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
127
CY2023Q2 us-gaap Interest Expense
InterestExpense
469952
CY2022Q2 us-gaap Interest Expense
InterestExpense
276524
us-gaap Interest Expense
InterestExpense
936183
us-gaap Interest Expense
InterestExpense
582619
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-681483
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-294594
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1150127
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-609322
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
346415
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
899780
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1560942
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2055474
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
125439
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
265061
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
573154
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
588708
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
220976
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
634719
us-gaap Net Income Loss
NetIncomeLoss
987788
us-gaap Net Income Loss
NetIncomeLoss
1466766
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8325101
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8437544
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8395307
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8479071
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8331911
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8553085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8402538
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8643106
us-gaap Profit Loss
ProfitLoss
987788
us-gaap Profit Loss
ProfitLoss
1466766
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
724890
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
760759
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-187825
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-152538
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6696
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-26830
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Share Based Compensation
ShareBasedCompensation
469591
us-gaap Share Based Compensation
ShareBasedCompensation
149358
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
403040
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
399953
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
10862
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9777
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
155617
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
153876
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1041578
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
296934
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
83909
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
11217
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-410993
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-190803
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-17820
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
133566
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
56798
ccel Increase Decrease In Deposits And Other Assets
IncreaseDecreaseInDepositsAndOtherAssets
237521
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
609687
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
232778
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1369083
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-982399
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-157011
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-154035
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2521664
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2031279
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3633026
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3453969
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1833043
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
954607
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
400000
ccel Payment Of Duke License Agreement
PaymentOfDukeLicenseAgreement
5000000
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
179306
ccel Proceeds From Liquidation Of Marketable Securities
ProceedsFromLiquidationOfMarketableSecurities
0
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1082923
ccel Payments To Acquire Marketable Securities And Other Investments
PaymentsToAcquireMarketableSecuritiesAndOtherInvestments
1142212
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
359752
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1127669
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2776908
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5969150
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
791452
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1425455
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
77126
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1550000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
500000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
ccel Payment Of Earnout
PaymentOfEarnout
67500
ccel Payment Of Earnout
PaymentOfEarnout
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1436078
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2943455
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-579960
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5458636
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1703958
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8263088
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1123998
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2804452
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
737867
ccel Lease Liability Arising From Right Of Use Asset
LeaseLiabilityArisingFromRightOfUseAsset
0
ccel Construction Costs Payable
ConstructionCostsPayable
1841254
ccel Construction Costs Payable
ConstructionCostsPayable
0
us-gaap Interest Paid Net
InterestPaidNet
869076
us-gaap Interest Paid Net
InterestPaidNet
483641
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
983647
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
756133
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-687517
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
156417
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
548251
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
220976
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1524302
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
469591
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
791452
us-gaap Net Income Loss
NetIncomeLoss
987788
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-858375
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4251277
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
117462
CY2022Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
596475
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
634719
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4406983
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
4184314
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
149358
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1425455
us-gaap Net Income Loss
NetIncomeLoss
1466766
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4406983
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
48108050
CY2023Q2 ccel Revenue Remaining Performance Obligation Next Twelve Months
RevenueRemainingPerformanceObligationNextTwelveMonths
9455539
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2005Q4 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
50000
CY2012Q1 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
75000
CY2017Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
100000
CY2023Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
10958
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
21390
CY2022Q2 us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
12169
us-gaap Sales Commissions And Fees
SalesCommissionsAndFees
27321
CY2023Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
28512
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
54948
CY2022Q2 ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
27170
ccel Increase Decrease In Capitalized Contract Cost
IncreaseDecreaseInCapitalizedContractCost
51759
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
654116
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6682479
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9455539
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9586327
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
38652511
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
36000059
CY2023Q2 ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
ccel Impairment Of Contract Assets
ImpairmentOfContractAssets
0
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
615628
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
54948
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
16460
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
654116
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6043941
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
21299426
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
20660888
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6682479
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
45586386
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
13557161
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
11035497
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
48108050
CY2021Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
535522
ccel Contract With Customer Asset Net Current Additions
ContractWithCustomerAssetNetCurrentAdditions
51759
ccel Contract With Customer Asset Net Current Deductions
ContractWithCustomerAssetNetCurrentDeductions
14238
CY2022Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
573043
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5253173
ccel Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
18402414
ccel Accounts Receivable Net Current Deductions
AccountsReceivableNetCurrentDeductions
18505433
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5150154
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40632910
ccel Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
11840456
ccel Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
9809177
CY2022Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
42664189
CY2023Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
470000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
157000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117000
CY2022Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-18000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-27000
CY2023Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
11000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
7000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-223974
us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product Warranty and Cryo-Cell Cares</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Program</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2005, the Company began providing its customers that enrolled after December 2005 a payment warranty under which the Company agrees to pay $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">its client if the umbilical cord blood product retrieved is used for a stem cell transplant for the donor or an immediate family member and fails to engraft, subject to various restrictions. Effective February 1, 2012, the Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payment warranty to a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> payment warranty to all of its new clients. Effective June 1, 2017, the Company increased the payment warranty to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to all new clients who choose the premium processing method, PrepaCyte CB. The product warranty is available to clients who enroll under this structure for as long as the specimen is stored with the Company. The Company has not experienced any claims under the warranty program nor has it incurred costs related to these warranties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As discussed above, the Company has determined that the payment warranty represents variable consideration payable to the customer. In accordance with ASC 606, the Company has concluded the payment warranty be fully constrained under the most likely amount method; therefore, the transaction price does not reflect any expectation of service level credits at May 31, 2023 and November 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. At the end of each reporting period, the Company shall update the estimated transaction price related to the payment guarantee including updating its assessment of whether an estimate of variable consideration is constrained to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.</span></p>
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2005Q4 ccel Payment Warranty
PaymentWarranty
50000
CY2012Q1 ccel Increased Payment Warranty
IncreasedPaymentWarranty
75000
CY2017Q2 ccel Increased Payment Warranty
IncreasedPaymentWarranty
100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7772690
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7633217
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2143186
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2201540
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1027898
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1194374
CY2023Q2 us-gaap Interest Expense
InterestExpense
469952
CY2022Q2 us-gaap Interest Expense
InterestExpense
276524
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15597105
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14891748
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4210550
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4304742
us-gaap Operating Income Loss
OperatingIncomeLoss
2711069
us-gaap Operating Income Loss
OperatingIncomeLoss
2664796
us-gaap Interest Expense
InterestExpense
936183
us-gaap Interest Expense
InterestExpense
582619
CY2023Q2 us-gaap Assets
Assets
68757708
CY2022Q4 us-gaap Assets
Assets
64888054
CY2023Q2 ccel Inventory Collection Kits
InventoryCollectionKits
49629
CY2022Q4 ccel Inventory Collection Kits
InventoryCollectionKits
41463
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7718
CY2023Q2 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
9715581
CY2022Q4 ccel Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
10126574
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1415121
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1463312
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48000
CY2023Q2 us-gaap Ratio Of Indebtedness To Net Capital1
RatioOfIndebtednessToNetCapital1
3.50
ccel Minimum Debt Service Coverage Ratio
MinimumDebtServiceCoverageRatio
1.25
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
8664138
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
8730402
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
158456
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
150527
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
8505682
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
8579875
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
8664138
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
8730402
CY2023Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
209624
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
417543
CY2022Q2 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
9357
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
27892
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
220976
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
634719
us-gaap Net Income Loss
NetIncomeLoss
987788
us-gaap Net Income Loss
NetIncomeLoss
1466766
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8325101
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8437544
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8395307
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8479071
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6810
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
115541
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7231
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
164035
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8331911
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8553085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8402538
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8643106
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
843678
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
843678
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
288381
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90100
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
398678
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P4Y9M10D
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.37
CY2023Q2 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
286385
CY2023Q2 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
7.44
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
95486
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
113000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
96193
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.29
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
112293
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.14
CY2011Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1000000
CY2012Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
3000000
CY2015Q2 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
6000000
CY2016Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
8000000
us-gaap Treasury Stock Acquired Repurchase Authorization
TreasuryStockAcquiredRepurchaseAuthorization
open market purchases, privately negotiated block trades, unsolicited negotiated transactions, and/or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission
CY2023Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
6560832
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
6347490
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1188284
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
606034
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
224729
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
297691
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
967116
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
313298
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1191845
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
610989
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
153381
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
306762
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
435970
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
458026
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
38247
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
200541
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1191845
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M29D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y29D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.035
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
88918
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
85964
us-gaap Operating Lease Payments
OperatingLeasePayments
177313
us-gaap Operating Lease Payments
OperatingLeasePayments
171928

Files In Submission

Name View Source Status
0000950170-23-033057-index-headers.html Edgar Link pending
0000950170-23-033057-index.html Edgar Link pending
0000950170-23-033057.txt Edgar Link pending
0000950170-23-033057-xbrl.zip Edgar Link pending
ccel-20230531.htm Edgar Link pending
ccel-20230531.xsd Edgar Link pending
ccel-ex31_1.htm Edgar Link pending
ccel-ex31_2.htm Edgar Link pending
ccel-ex31_3.htm Edgar Link pending
ccel-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
ccel-20230531_lab.xml Edgar Link unprocessable
ccel-20230531_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ccel-20230531_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ccel-20230531_cal.xml Edgar Link unprocessable
ccel-20230531_def.xml Edgar Link unprocessable